Global Immune Checkpoint Inhibitors Market Outlook 2022
Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.
According to the report “Global Immune Checkpoint Inhibitors Market Outlook 2022”, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.
The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.
On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
According to the report “Global Immune Checkpoint Inhibitors Market Outlook 2022”, the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors.
Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors.
The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch there products.
On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.
A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. IMMUNE CHECKPOINT INHIBITORS: OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments
4.2.2 Sky-High Development Costs of Cancer Immunotherapies
4.2.3 High Cost of Treatment
4.2.4 Lack of Awareness
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET OUTLOOK 2022
6. GLOBAL IMMUNE CHECKPOINT INHIBITORS SALES, BY PRODUCT CLASS
6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.1.1 Yervoy (Ipilimumab)
6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
6.2.1 Tecentriq (Atezolizumab)
6.2.2 Bavencio (Avelumab)
6.2.3 Imfinzi (Durvalumab)
6.2.4 Opdivo (Nivolumab)
6.2.5 Keytruda (Pembrolizumab)
7. APPLICATION OF IMMUNE CHECKPOINT INHIBITORS IN MAJOR INDICATIONS
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. TRENDS & DEVELOPMENTS
8.1 Lucrative Investment Trend
8.2 Emergence of Targeted and Combination Therapies
8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
9. STRATEGIC COLLABORATIONS & ALLIANCES IN THE IMMUNE CHECKPOINT INHIBITORS MARKET
10. PIPELINE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS
11. KEY PLAYERS ANALYSIS
11.1 Genentech, Inc. (A Member of the Roche Group)
11.2 CureTech Ltd.
11.3 NewLink Genetics Corporation
11.4 Novartis AG
11.5 Bristol-Myers Squibb
11.6 Merck & Co., Inc.
11.7 AstraZeneca Plc
11.8 Pfizer Inc
11.9 Ono Pharmaceutical Co., Ltd.
11.10 EMD Serono, Inc.
2. RESEARCH METHODOLOGY
3. IMMUNE CHECKPOINT INHIBITORS: OVERVIEW
4. MARKET DYNAMICS
4.1 Drivers
4.1.1 Increasing Cancer Incidences
4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
4.1.3 Growing Geriatric Population
4.1.4 High Healthcare Spending in Developed Economies
4.1.5 Strong Pipeline
4.1.6 Increasing Efficacy in a Wide Variety of Indications
4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
4.2 Challenges
4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments
4.2.2 Sky-High Development Costs of Cancer Immunotherapies
4.2.3 High Cost of Treatment
4.2.4 Lack of Awareness
4.3 Opportunities
4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity
4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET OUTLOOK 2022
6. GLOBAL IMMUNE CHECKPOINT INHIBITORS SALES, BY PRODUCT CLASS
6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
6.1.1 Yervoy (Ipilimumab)
6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
6.2.1 Tecentriq (Atezolizumab)
6.2.2 Bavencio (Avelumab)
6.2.3 Imfinzi (Durvalumab)
6.2.4 Opdivo (Nivolumab)
6.2.5 Keytruda (Pembrolizumab)
7. APPLICATION OF IMMUNE CHECKPOINT INHIBITORS IN MAJOR INDICATIONS
7.1 Head & Neck Cancer
7.2 Lung Cancer
7.3 Melanoma
7.4 Lymphoma
7.5 Leukemia
7.6 Others
8. TRENDS & DEVELOPMENTS
8.1 Lucrative Investment Trend
8.2 Emergence of Targeted and Combination Therapies
8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
9. STRATEGIC COLLABORATIONS & ALLIANCES IN THE IMMUNE CHECKPOINT INHIBITORS MARKET
10. PIPELINE ANALYSIS OF IMMUNE CHECKPOINT INHIBITORS
11. KEY PLAYERS ANALYSIS
11.1 Genentech, Inc. (A Member of the Roche Group)
11.2 CureTech Ltd.
11.3 NewLink Genetics Corporation
11.4 Novartis AG
11.5 Bristol-Myers Squibb
11.6 Merck & Co., Inc.
11.7 AstraZeneca Plc
11.8 Pfizer Inc
11.9 Ono Pharmaceutical Co., Ltd.
11.10 EMD Serono, Inc.
LIST OF FIGURES:
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018
Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017
Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021
Figure 6-4: Global - Imfinzi Market (Million US$), 2017
Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016
Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016
Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)
Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016
Figure 10-2: Global – Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016
Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016
Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016
Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016
Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016
Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016
Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016
Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016
Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016
Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030
Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030
Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050
Figure 4-4: Expected Combination Regimen Launches in Oncology
Figure 5-1: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022
Figure 6-1: Global - Yervoy Market (Million US$), 2012-2018
Figure 6-2: Global - Tecentriq Market (Million US$), 2016 & 2017
Figure 6-3: Global - Bavencio Market (Million US$), 2017-2021
Figure 6-4: Global - Imfinzi Market (Million US$), 2017
Figure 6-5: Global - Opdivo Market (Million US$), 2014-2016
Figure 6-6: Global - Keytruda Market (Million US$), 2014-2016
Figure 7-1: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-2: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-3: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-4: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-5: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-6: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-7: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-8: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-9: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-10: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 7-11: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016
Figure 7-12: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016
Figure 8-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016
Figure 8-2: Major Investors in Immuno-Oncology Market (2015-2016)
Figure 8-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations
Figure 10-1: Global - Immune Checkpoint Inhibitors Pipeline Analysis by Product Type (%), 2016
Figure 10-2: Global – Immune Checkpoint Inhibitors Pipeline Analysis by Phase (%), 2016
Figure 11-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016
Figure 11-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016
Figure 11-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016
Figure 11-4: Novartis AG - Breakup of Sales by Business Segment (%), 2016
Figure 11-5: Novartis AG - Breakup of Pharmaceuticals Division Sales by Segment (%), 2016
Figure 11-6: Novartis AG - Breakup of Sales by Geography (%), 2016
Figure 11-7: Bristol Myers Squibb - Revenue by Business Segments (%), 2016
Figure 11-8: Bristol Myers Squibb - Revenue by Geography (%), 2016
Figure 11-9: Merck & Co., Inc. - Revenue by Business Segments (%), 2016
Figure 11-10: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016
Figure 11-11: Merck & Co., Inc. - Revenue by Geography (%), 2016
Figure 11-12: AstraZeneca Plc - Revenue by Business Segments (%), 2016
Figure 11-13: AstraZeneca Plc - Revenue by Geography (%), 2016
Figure 11-14: Pfizer Inc - Revenue by Business Segments (%), 2016
Figure 11-15: Pfizer Inc - Revenue by Geography (%), 2016
LIST OF TABLES:
Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline
Table 6-1: Ongoing Trials for Yervoy
Table 6-2: Ongoing Trials for Opdivo
Table 6-3: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020
Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations
Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market
Table 10-1: Active Immune Checkpoint Inhibitors Programs
Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline
Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-3: Genentech, Inc. – Product Pipeline
Table 11-4: CureTech Ltd. - Product Pipeline
Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016
Table 11-6: NewLink Genetics Corporation - Product Pipeline
Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016
Table 11-8: Novartis AG - Product Pipeline
Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors
Table 11-11: Bristol Myers Squibb - Product Pipeline
Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-14: Merck & Co., Inc. - Product Pipeline
Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors
Table 11-17: AstraZeneca Plc - Product Pipeline
Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016
Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors
Table 11-20: Pfizer Inc - Product Pipeline
Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016
Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors
Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline
Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-25: EMD Serono, Inc. - Product Pipeline
Table 4-1: Immune Checkpoint Inhibitors - Late Stage Research Pipeline
Table 6-1: Ongoing Trials for Yervoy
Table 6-2: Ongoing Trials for Opdivo
Table 6-3: Ongoing Trials for Keytruda
Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020
Table 8-1: Selected Immuno-Oncology and Targeted Therapy Combinations
Table 9-1: Strategic Collaborations in the Immune Checkpoint Inhibitors Market
Table 10-1: Active Immune Checkpoint Inhibitors Programs
Table 10-2: Global - Immune Checkpoint Inhibitors Product Pipeline
Table 11-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016
Table 11-2: Genentech, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-3: Genentech, Inc. – Product Pipeline
Table 11-4: CureTech Ltd. - Product Pipeline
Table 11-5: NewLink Genetics Corporation- Key Financials (Million US$), 2014-2016
Table 11-6: NewLink Genetics Corporation - Product Pipeline
Table 11-7: Novartis AG - Key Financials (Billion US$), 2014-2016
Table 11-8: Novartis AG - Product Pipeline
Table 11-9: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016
Table 11-10: Bristol Myers Squibb - Commercialized Immune Checkpoint Inhibitors
Table 11-11: Bristol Myers Squibb - Product Pipeline
Table 11-12: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016
Table 11-13: Merck & Co., Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-14: Merck & Co., Inc. - Product Pipeline
Table 11-15: AstraZeneca Plc - Key Financials (Million US$), 2014-2016
Table 11-16: AstraZeneca Plc - Commercialized Immune Checkpoint Inhibitors
Table 11-17: AstraZeneca Plc - Product Pipeline
Table 11-18: Pfizer Inc - Key Financials (Billion US$), 2014-2016
Table 11-19: Pfizer Inc - Commercialized Immune Checkpoint Inhibitors
Table 11-20: Pfizer Inc - Product Pipeline
Table 11-21: Ono Pharmaceutical Co., Ltd. - Key Financials (Million US$), FY2014-FY2016
Table 11-22: Ono Pharmaceutical Co., Ltd. - Commercialized Immune Checkpoint Inhibitors
Table 11-23: Ono Pharmaceutical Co., Ltd. - Product Pipeline
Table 11-24: EMD Serono, Inc. - Commercialized Immune Checkpoint Inhibitors
Table 11-25: EMD Serono, Inc. - Product Pipeline
